One of Metro Detroit’s most promising startups has a new leader who comes with a history of shepherding biotech companies through to acquisition.
Delphinus Medical Technologies has hired Mark Forchette as its president and CEO. Forchette served as OptiMedica Corp’s president and CEO before taking the job. The company specialized in ophthalmic medical devices. He led OptiMedica Corp. through commercialization, successfully completed multiple rounds of financing, and oversaw the company’s acquisition by Abbott Laboratories last year. He says he sees the same sort of potential with Delphinus Medical Technologies
"I see an incredible technology that can improve women's health," Forchette says.
Delphinus Medical Technologies makes SoftVue, a "whole breast ultrasound tomography system" that helps diagnose breast cancer more effectively than traditional mammograms. The technology spun out of Wayne State University and the Karmanos Cancer Institute
in 2009. It has raised a $12 million Series A round in 2010 and a $11 million Series B last year. It has since hired 15 people, expanding its staff to 35 employees.
"We're in position now where we have on-boarded a lot of talent," Forchette says. "We're really excited about that."
That team will work to gain technical credibility with doctors and health systems, enabling them to thoroughly adopt the SoftVue technology.
"We have to do that clinically," Forchette says. "It's a process of incorporating physicians deeply within the company."
Source: Mark Forchette, president & CEO of Delphinus Medical Technologies
Writer: Jon Zemke
Read more about Metro Detroit's growing entrepreneurial ecosystem at SEMichiganStartup.com.